News
With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...
AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback